The state of North Carolina currently has 12 active clinical trials seeking participants for Head and Neck Cancer research studies. These trials are conducted in various cities, including Durham, Winston-Salem, Charlotte and Chapel Hill.
A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors
Recruiting
The goal of this clinical trial is to test a new drug plus standard treatment compared with standard treatment alone in patients with advanced head and neck squamous cell carcinoma and cholangiocarcinoma. The main questions it aims to answer are: is the new drug plus standard treatment safe and tolerable is the new drug plus standard treatment more effective than standard treatment
Gender:
All
Ages:
18 years and above
Trial Updated:
03/22/2024
Locations: Novant Health Cancer Institute, Charlotte, North Carolina +2 locations
Conditions: Head and Neck Squamous Cell Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer, Cholangiocarcinoma, Gallbladder Cancer, Gallbladder Carcinoma, Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma, Bile Duct Cancer, Cancer of the Head and Neck, HNSCC, Oropharynx Cancer, Oral Cavity Cancer, Hypopharynx Cancer, Larynx Cancer, Oral Cavity Squamous Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck, Squamous Cell Carcinoma of the Head and Neck, Squamous Cell Carcinoma of the Larynx, Squamous Cell Carcinoma of the Hypopharynx, Squamous Cell Carcinoma of the Oral Cavity, Squamous Cell Carcinoma of the Oropharynx, Gall Bladder Cancer, Gall Bladder Carcinoma, Oropharynx Squamous Cell Carcinoma, Hypopharynx Squamous Cell Carcinoma, Larynx Squamous Cell Carcinoma
A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors
Recruiting
TScan Therapeutics is developing cellular therapies across multiple solid tumors in which autologous participant-derived T cells are engineered to express a T cell receptor that recognizes cancer-associated antigens presented on specific Human Leukocyte Antigen (HLA) molecules. The purpose of this screening study is to collect samples to conduct HLA genotyping, HLA Loss of Heterozygosity (LOH) and expression of Tumor-associated Antigens (TAA) testing. These results will be used to determine if s... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/20/2024
Locations: University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
Conditions: Head and Neck Cancer, Cervical Cancer, Non Small Cell Lung Cancer, Melanoma, Ovarian Cancer, HPV16 Related Cancers
MEM-288 Oncolytic Virus Alone and in Combination With Nivolumab in Solid Tumors Including Non-Small Cell Lung Cancer
Recruiting
This phase I trial is designed in two parts. First as an open-label, dose escalation trial of MEM-288 monotherapy in which investigators aim to find the maximum tolerated dose (MTD) and recommended phase II dose (RP2D). Subjects with selected solid tumors including non-small cell lung cancer (NSCLC) who have a tumor lesion which is accessible for injection will undergo intratumoral injection of MEM-288. Following completion of the monotherapy study portion of the study, an expansion arm is desig... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/28/2024
Locations: Duke Cancer Institute, Durham, North Carolina
Conditions: Solid Tumor, Advanced Cancer, Metastatic Cancer, Non Small Cell Lung Cancer, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, Melanoma, Pancreatic Cancer, Triple Negative Breast Cancer, Head and Neck Cancer
ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)
Recruiting
This study will investigate the safety and tolerability of ADP-A2M4CD8 T-cell therapy in subjects who have the appropriate human leukocyte antigen (HLA) and MAGE-A4 tumor antigen. Tumor indications include endometrial, esophageal, esophagogastric junction (EGJ), gastric, head and neck, melanoma, non-small cell lung (NSCLC), ovarian or urothelial cancer.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
02/15/2024
Locations: Duke University Medical Center, Duke Cancer Institute, Durham, North Carolina
Conditions: Esophageal Cancer, Ovarian Cancer, Endometrial Cancer, Esophagogastric Junction (EGJ), Gastric (Stomach) Cancer, Head and Neck Cancer, Melanoma, Non-small Cell Lung (NSCLC), Urothelial Cancer
CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)
Recruiting
The objective of this study is to assess safety and efficacy of CAB-ROR2-ADC in solid tumors
Gender:
All
Ages:
18 years and above
Trial Updated:
01/29/2024
Locations: FirstHealth Outpatient Cancer Center, Pinehurst, North Carolina +1 locations
Conditions: Non Small Cell Lung Cancer, Triple Negative Breast Cancer, Melanoma, Head and Neck Cancer
Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Recruiting
This is a Phase 1, open-label, first-in-human study of CTX-471 administered as a monotherapy or in combination with pembrolizumab in patients with metastatic or locally advanced malignancies that have progressed while receiving an approved PD-1 or PD-L1 inhibitor. The study will be conducted in 2 treatment arms (Monotherapy Arm 1 and Combination Arm 2). Each arm will have two parts: Part 1 Dose Escalation and Part 2 Dose Expansion.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/29/2024
Locations: Duke University School of Medicine, Durham, North Carolina
Conditions: Locally Advanced Solid Tumor, Metastatic Cancer, Non-small Cell Lung Cancer, Small Cell Lung Cancer, Mesothelioma, Melanoma, Head and Neck Cancer
MucoLox Formulation to Mitigate Mucositis Symptoms in Head/Neck Cancer
Recruiting
This study will examine if the administration of prophylactic MucoLox formulation versus sodium bicarbonate mouthwash in subjects with head/neck cancer receiving radiation ± chemotherapy will result in significantly fewer subjects experiencing severe mucositis.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/17/2024
Locations: Levine Cancer Institute, Charlotte, North Carolina
Conditions: Mucositis Oral, Head and Neck Cancer
A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors
Recruiting
TScan Therapeutics is developing cellular therapies across multiple solid tumors in which autologous participant-derived T cells are engineered to express a T cell receptor that recognizes cancer-associated antigens presented on specific Human Leukocyte Antigen (HLA) molecules. This is a multi-center, non-randomized, multi-arm, open-label, basket study evaluating the safety and preliminary efficacy of single and repeat dose regimens of TCR'Ts as monotherapies and as T-Plex combinations after ly... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
01/09/2024
Locations: University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
Conditions: Head and Neck Cancer, Cervical Cancer, Non-small Cell Carcinoma, Melanoma, Ovarian Cancer, Anogenital Cancers, HPV - Anogenital Human Papilloma Virus Infection, HPV-Related Cervical Carcinoma, HPV-Related Carcinoma, HPV-Related Squamous Cell Carcinoma, HPV-Related Malignancy, HPV-Related Adenocarcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma, HPV-Related Adenosquamous Carcinoma, HPV-Associated Vaginal Adenocarcinoma, HPV-Related Endocervical Adenocarcinoma, HPV-Related Anal Squamous Cell Carcinoma, HPV-Related Verrucous Carcinoma, HPV-Related Penile Squamous Cell Carcinoma, HPV-Related Vulvar Squamous Cell Carcinoma, HPV Positive Rectal Squamous Cell Carcinoma
Carotid Ultrasound to Identify Head and Neck Cancer Survivors With High Cardiovascular Risk After Radiation Therapy
Recruiting
The purpose of this research study is to understand how radiation therapy may affect blood vessels in the neck called the carotid arteries. Investigators want to look at narrowing of the artery or thickening of the walls of the arteries.
Gender:
All
Ages:
18 years and above
Trial Updated:
12/14/2023
Locations: Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina
Conditions: Head and Neck Cancer, Carotid Artery Stenosis, Cardiovascular Complication
Multi-Site Trial of Navigation vs Treatment as Usual for Delays in Starting Adjuvant Therapy
Recruiting
The goal of this clinical trial is to compare the effectiveness of a navigation-based multilevel intervention (ENDURE) with treatment as usual at decreasing delays starting guideline-adherent postoperative radiation therapy among patients with head and neck cancer. The main questions the trial aims to answer are: Does ENDURE decrease delays starting PORT relative to treatment as usual? Does ENDURE decrease racial disparities in delays starting PORT relative to treatment as usual What are the me... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/28/2023
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Oropharynx Cancer, Oral Cavity Cancer, Larynx Cancer
PRospective rEgistry OF Advanced Stage cancER (PREFER) Patients to Assess Prevalence of Actionable Biomarkers and Driver Mutations to Address Disparities in Precision Medicine
Recruiting
The objective of this Study is to collect, process, and transfer biologic samples such as blood and/or tissue biopsies to determine the concordance of detected alterations obtained through liquid biopsy analyses compared to next generation sequencing of time-matched or archival tissue specimens from individuals with advanced solid tumors. Examples of locally advanced and metastatic tumors include stage III and IV cancers (ex. lung, breast, all gastrointestinal malignancies, all gynecologic mali... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/26/2023
Locations: Clinical Site, Huntersville, North Carolina
Conditions: Lung Cancer, Ovarian Cancer, Uterine Cancer, Colorectal Cancer, Stomach Cancer, Esophageal Cancer, Pancreatic Cancer, Melanoma, Breast Cancer, Head and Neck Cancer, Soft Tissue Sarcoma, Rhabdomyosarcoma, Prostate Cancer
CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors
Recruiting
Phase 1, first-in-human, open label study of CAR macrophages in HER2 overexpressing solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
12/15/2022
Locations: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
Conditions: HER2-positive, Adenocarcinoma, Bile Duct Cancer, Biliary Tract Cancer, Bladder Cancer, Breast Cancer, Breast Neoplasm, Carcinoma, Ductal, Carcinoma, Hepatocellular, Cancer, Carcinoma, Ovarian Epithelial, Carcinoma, Small Cell, Carcinoma, Squamous, Carcinoma, Transitional Cell, Colorectal Cancer, Esophagogastric Junction Neoplasms, Inflammatory Breast Cancer, Stomach Neoplasms, Malignant Neoplasms, Ovarian Neoplasms, Pancreatic Cancer, HER2-positive Solid Tumors, HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER-2 Protein Overexpression, HER-2 Gene Amplification, Lung Cancer, Non-Small-Cell, Prostate Cancer, Head and Neck Cancer, Endometrial Cancer, Lung Cancer, Small Cell